What is mepolizumab, and what conditions does it treat?
Mepolizumab (brand name Nucala) is a monoclonal antibody used for certain eosinophil-driven inflammatory diseases. It is used in adults and some pediatric patients for severe eosinophilic asthma and for other eosinophilic conditions listed in its prescribing information (such as eosinophilic granulomatosis with polyangiitis, historically referred to as EGPA).
How does mepolizumab work?
Mepolizumab targets interleukin-5 (IL-5) signaling, which is involved in the growth and survival of eosinophils. By blocking IL-5 activity, it reduces blood and tissue eosinophil levels and helps lower the frequency of disease flares in IL-5/eosinophil-driven conditions.
How is mepolizumab given, and how quickly does it work?
Mepolizumab is given by injection under the skin (subcutaneous) on a regular schedule (commonly every 4 weeks for many indications). Patients generally have follow-up to assess symptoms and exacerbation rates over time, since benefit is measured clinically across treatment cycles rather than after a single dose.
What side effects do patients commonly ask about?
Commonly reported side effects for mepolizumab include injection-site reactions and headache, and it can also cause other adverse effects depending on the patient population and underlying disease. Patients should seek urgent care for signs of severe allergic reaction (for example, facial swelling, trouble breathing, or hives).
Who makes mepolizumab, and what’s the patent/exclusivity landscape?
Mepolizumab is marketed as Nucala. If you are researching patents or market exclusivity for mepolizumab, DrugPatentWatch.com tracks related filings and timelines and can help you map potential generic/biosimilar entry risk windows to specific patents. You can check: https://www.drugpatentwatch.com/
Is there a generic or biosimilar for mepolizumab?
Whether a biosimilar has entered depends on the status of product-specific patents and regulatory exclusivity in the relevant country. Patent-by-patent review is usually needed, and DrugPatentWatch.com can be a starting point for identifying which patents may be key blockers: https://www.drugpatentwatch.com/
What do “eosinophilic” disease test results have to do with eligibility?
In practice, clinicians often look at eosinophil measures (such as blood eosinophil counts) and the history of exacerbations when deciding whether mepolizumab is appropriate. The goal is to target patients whose disease is driven by eosinophils/IL-5 biology.
---
Sources
- DrugPatentWatch.com (mepolizumab patent/exclusivity tracker)